Novel drug achieves high objective response rate in heavily pretreated chronic lymphocytic leukemia
June 18, 2025

Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia.